Alycia Halladay

Last updated
Alycia Kay Halladay
Alma mater Rutgers University
OccupationScience researcher
Known forAutism research, Autism Science Foundation
Scientific career
Fields Biological psychiatry
Institutions Autism Science Foundation
Thesis Interaction of changes in dopamine signaling and expression of the Eph family tyrosine kinase receptors in mice  (2001)

Alycia Kay Halladay is Chief Science Officer at the Autism Science Foundation. Until 2014, she served as the senior director of environmental and clinical sciences for Autism Speaks. She originally joined the National Alliance for Autism Research in 2005 before it merged with Autism Speaks, and was named the associate director of research for environmental sciences in 2007. [1] She also serves at an adjunct professor in the Pharmacology and Toxicology Department at Rutgers University.

Contents

Education

After obtaining her bachelor's degree from the University of Texas at Austin, Halladay received her M.S. (1998) and Ph.D. (2001) in psychology, both from Rutgers University, where she completed a postdoctoral fellowship in pharmacology and toxicology. [2]

Autism

At the Autism Science Foundation, Halladay leads the science program of ASF, which includes pre and post doctoral fellowships, accelerator grants, as well as large scale projects including the Autism Sisters Project the outreach and communications behind the Autism BrainNet. She also has experience managing consortium and multidisciplinary initiatives such as gene/environment interactions initiative, the High Risk Baby Siblings Consortium and the Toddler Treatment Network. [3] She was interviewed by Parade magazine in 2013, saying, "There are likely thousands of genes that contribute to risk. However, there are also some environmental factors that contribute to risk. These include maternal infection and certain chemical and medical exposures." [4] She has also said that early intervention "can make a real lifetime of difference" [5] with regard to improving symptoms of autism in children, and after a study on folic acid and autism was published in JAMA , Halladay said that taking folic acid during pregnancy was "a relatively inexpensive way that parents can take action to possibly prevent risk of tube birth defects and autism". [6]

Related Research Articles

<span class="mw-page-title-main">Folate</span> Vitamin B9; nutrient essential for DNA synthesis

Folate, also known as vitamin B9 and folacin, is one of the B vitamins. Manufactured folic acid, which is converted into folate by the body, is used as a dietary supplement and in food fortification as it is more stable during processing and storage. Folate is required for the body to make DNA and RNA and metabolise amino acids necessary for cell division. As humans cannot make folate, it is required in the diet, making it an essential nutrient. It occurs naturally in many foods. The recommended adult daily intake of folate in the U.S. is 400 micrograms from foods or dietary supplements.

<span class="mw-page-title-main">Chelation therapy</span> Medical procedure to remove heavy metals from the body

Chelation therapy is a medical procedure that involves the administration of chelating agents to remove heavy metals from the body. Chelation therapy has a long history of use in clinical toxicology and remains in use for some very specific medical treatments, although it is administered under very careful medical supervision due to various inherent risks, including the mobilization of mercury and other metals through the brain and other parts of the body by the use of weak chelating agents that unbind with metals before elimination, exacerbating existing damage. To avoid mobilization, some practitioners of chelation use strong chelators, such as selenium, taken at low doses over a long period of time.

Autism spectrum disorder (ASD) is a developmental disorder that begins in early childhood, persists throughout adulthood, and affects three crucial areas of development: communication, social interaction and restricted patterns of behavior. There are many conditions comorbid to autism spectrum disorder such as fragile X syndrome and epilepsy.

An environmental factor, ecological factor or eco factor is any factor, abiotic or biotic, that influences living organisms. Abiotic factors include ambient temperature, amount of sunlight, and pH of the water soil in which an organism lives. Biotic factors would include the availability of food organisms and the presence of biological specificity, competitors, predators, and parasites.

Toxicogenomics is a subdiscipline of pharmacology that deals with the collection, interpretation, and storage of information about gene and protein activity within a particular cell or tissue of an organism in response to exposure to toxic substances. Toxicogenomics combines toxicology with genomics or other high-throughput molecular profiling technologies such as transcriptomics, proteomics and metabolomics. Toxicogenomics endeavors to elucidate the molecular mechanisms evolved in the expression of toxicity, and to derive molecular expression patterns that predict toxicity or the genetic susceptibility to it.

<span class="mw-page-title-main">Neural tube defect</span> Group of birth defects of the brain or spinal cord

Neural tube defects (NTDs) are a group of birth defects in which an opening in the spine or cranium remains from early in human development. In the third week of pregnancy called gastrulation, specialized cells on the dorsal side of the embryo begin to change shape and form the neural tube. When the neural tube does not close completely, an NTD develops.

<span class="mw-page-title-main">Heritability of autism</span>

The heritability of autism is the proportion of differences in expression of autism that can be explained by genetic variation; if the heritability of a condition is high, then the condition is considered to be primarily genetic. Autism has a strong genetic basis. Although the genetics of autism are complex, autism spectrum disorder (ASD) is explained more by multigene effects than by rare mutations with large effects.

<span class="mw-page-title-main">Causes of autism</span> Proposed causes of autism

Many causes of autism have been proposed, but understanding of the theory of causation of autism, or otherwise known as autism spectrum disorder (ASD) is incomplete. Attempts have been made to incorporate the known genetic and environmental causes into a comprehensive causative framework. ASD is a complex developmental condition marked by persistent challenges to social interaction, speech and nonverbal communication, and restricted/repetitive behaviors and its phenotypes vary significantly.

<span class="mw-page-title-main">Autism spectrum</span> Neurodevelopmental disorder

Autism, formally called autism spectrum disorder (ASD) and autism spectrum condition (ASC), is a neurodevelopmental disorder characterized by deficits in social communication and social interaction, and repetitive or restricted patterns of behaviors, interests, or activities, which can include hyper- and hyporeactivity to sensory input. Autism is a spectrum disorder, meaning that it can manifest very differently in each person. For example, some are nonspeaking, while others have proficient spoken language. Because of this, there is wide variation in the support needs of people across the autism spectrum.

The Autism Science Foundation (ASF) is a non-profit organization that funds evidence-based autism research and supports autism families. The organization was founded in April 2009 by Alison Tepper Singer, a former senior executive of Autism Speaks and the longest-serving public member of the Interagency Autism Coordinating Committee (IACC), and Karen Margulis London, co-founder of the National Alliance for Autism Research. Both Singer and London are parents of autistic children.

Autism spectrum disorder (ASD) refers to a variety of conditions typically identified by challenges with social skills, communication, speech, and repetitive sensory-motor behaviors. The 11th International Classification of Diseases (ICD-11), released in January 2021, characterizes ASD by the associated deficits in the ability to initiate and sustain two-way social communication and restricted or repetitive behavior unusual for the individual's age or situation. Although linked with early childhood, the symptoms can appear later as well. Symptoms can be detected before the age of two and experienced practitioners can give a reliable diagnosis by that age. However, official diagnosis may not occur until much older, even well into adulthood. There is a large degree of variation in how much support a person with ASD needs in day-to-day life. This can be classified by a further diagnosis of ASD level 1, level 2, or level 3. Of these, ASD level 3 describes people requiring very substantial support and who experience more severe symptoms. ASD-related deficits in nonverbal and verbal social skills can result in impediments in personal, family, social, educational, and occupational situations. This disorder tends to have a strong correlation with genetics along with other factors. More research is identifying ways in which epigenetics is linked to autism. Epigenetics generally refers to the ways in which chromatin structure is altered to affect gene expression. Mechanisms such as cytosine regulation and post-translational modifications of histones. Of the 215 genes contributing, to some extent in ASD, 42 have been found to be involved in epigenetic modification of gene expression. Some examples of ASD signs are specific or repeated behaviors, enhanced sensitivity to materials, being upset by changes in routine, appearing to show reduced interest in others, avoiding eye contact and limitations in social situations, as well as verbal communication. When social interaction becomes more important, some whose condition might have been overlooked suffer social and other exclusion and are more likely to have coexisting mental and physical conditions. Long-term problems include difficulties in daily living such as managing schedules, hypersensitivities, initiating and sustaining relationships, and maintaining jobs.

Behavioral epigenetics is the field of study examining the role of epigenetics in shaping animal and human behavior. It seeks to explain how nurture shapes nature, where nature refers to biological heredity and nurture refers to virtually everything that occurs during the life-span. Behavioral epigenetics attempts to provide a framework for understanding how the expression of genes is influenced by experiences and the environment to produce individual differences in behaviour, cognition, personality, and mental health.

<span class="mw-page-title-main">Jeffrey Brent</span> Medical toxicologist

Jeffrey A. Brent is a medical toxicologist who is a distinguished clinical professor of medicine and emergency medicine at the University of Colorado, School of Medicine. In addition, he is a professor at the Department of Environmental and Occupational Health at the Colorado School of Public Health. He is also the past president of the American Academy of Clinical Toxicology, was editor in chief of the journal Toxicological Reviews, and was a member of the board of directors of the American College of Medical Toxicology. Previously, most of Brent's research focused on the use of fomepizole as a treatment for both methanol and ethylene glycol poisoning, and he led a trial of this drug which resulted in the FDA approving it in December 1997. Currently, Brent serves as Director of the Toxicology Investigators Consortium, an NIH and FDA supported multi center research and surveillance group. Brent is also a senior editor of "Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient," originally published in 2005, and now in its second edition, which was published in 2017.

Hurair Vasken Aposhian was a Ph.D. toxicologist and an emeritus professor of molecular and cell biology at the University of Arizona, a post he held beginning in 1975. He is also a former professor of pharmacology at the medical school at said university. He received his bachelor's degree in chemistry, at Brown University, 1948. He received a master's degree and a PhD in physiological chemistry at the University of Rochester, where he published some scientific studies about the synthesis of isoalloxazine ring-containing compounds. He did a postdoctoral with Nobel Laureate Arthur Kornberg in the department of biochemistry at Stanford University School of Medicine. He has done sabbatical scholar-in-residence at MIT and at the University of California at San Diego. He is best known for his pioneering work on Succimer and Unithiol in the treatment of arsenic, mercury, lead and other heavy metals leading to FDA approval of succimer in childhood lead poisoning at levels over 40 ug/dl. Previous posts he had held include at Vanderbilt, Tufts University, and the University of Maryland. His views about mercury in vaccines and in dental amalgams go against the consensus of the medical community and are controversial.

Sandra Jill James is an American biochemist and autism researcher who studies metabolic autism biomarkers. She works at Arkansas Children's Hospital Research Institute, where she is the director of the Metabolic Genomics Laboratory, as well as the University of Arkansas for Medical Sciences's department of pediatrics, where she has worked since 2002. She is also a member of the Autism Speaks Treatment Advisory Board, and is also a scientific advisor to the autism foundation N of One. Her current research focuses on the role of epigenetics in causing autism, as well as the effectiveness of supplements as a treatment for autism and the potential existence of abnormal metabolism in autistic children. This research is funded by a 5-year grant from the National Institutes of Health entitled "Metabolic biomarkers of autism: predictive potential and genetic susceptibility," as well as by a grant from Autism Speaks.

David S. Baskin is a neurosurgeon who currently works at Houston Methodist Hospital as the Vice Chairman of the Department of Neurosurgery, the Director of the Residency Training program, and the Director of the Kenneth R. Peak Brain & Pituitary Tumor Center, and is also a professor of neurosurgery at Weill Cornell Medical College.

The CHARGE study, which stands for Childhood Autism Risks from Genetics and the Environment, was launched in 2003 by researchers at the MIND Institute. It describes its goal as to research the role of gene-environment interactions in influencing autism risk. Scientists involved in the research include Irva Hertz-Picciotto, who is the study's principal investigator. The study is funded by the National Institutes of Health. Over 1,000 families have participated in the study. The children in the study are divided into three groups: children with autism, children with developmental delay, and children chosen at random from the general population.

Danielle Marie Dick is an American psychologist. She is the inaugural director of the Rutgers Addiction Research Center at the Rutgers Brain Health Institute. She researches the genetic epidemiology of substance abuse and related behavioral disorders.

Jill Escher is a former attorney and real estate developer. She is the head of the Escher Fund for Autism, the immediate past president of the Autism Society of America San Francisco Bay Area chapter, and the president of the National Council on Severe Autism. Escher is a graduate of Stanford University and the UC Berkeley School of Law.

Nutritional epigenetics is a science that studies the effects of nutrition on gene expression and chromatin accessibility. It is a subcategory of nutritional genomics that focuses on the effects of bioactive food components on epigenetic events.

References

  1. Lajonchere, Clara (16 April 2007). "Autism Speaks™ Announces New Staff Structure for its Science Program". Autism Speaks . Retrieved 16 November 2013.
  2. "IACC Full Committee Meeting Speaker/Discussant Biographies - July 9, 2013". IACC. 2013-07-09. Retrieved 2014-01-05.
  3. "Environmental Epigenetics Symposium: About". www.autismepigenetics.org. Autism Epigenetics. Retrieved 25 December 2013.
  4. Marquez, Jennifer Rainey (29 April 2013). "Your Autism Questions—Answered!". Parade . Retrieved 15 November 2013.
  5. Sifferlin, Alexandra (20 August 2013). "Siblings of Autistic Children at a Higher Risk for the Disorder; Can That Risk Be Lowered?". Time . Retrieved 15 November 2013.
  6. Pearson, Catherine (12 February 2013). "Folic Acid Lowers Autism Risk By 40 Percent: Study". Huffington Post . Retrieved 15 November 2013.